Sign up Calendar Latest Topics
 
 
 


Reply
  Author   Comment  
MargaretB

Avatar / Picture

Goddess for Life
Registered:
Posts: 1,279
Reply with quote  #1 
Anyone on this chemo that can give me some helpful hints for my 32 year old coworker?

Margaret


Registered:
Posts: N/A
Reply with quote  #2 
Margaret, I wish I could.  Let me look around and see what I can find.

Amy
MargaretB

Avatar / Picture

Goddess for Life
Registered:
Posts: 1,279
Reply with quote  #3 
Thanks Amy.  I don't know anyone else who is taking this combo.  I know my coworker has had a tough time with it.

Margaret
nosurrender

Avatar / Picture

Moderator
Registered:
Posts: 7,476
Reply with quote  #4 
I did a lot of research on Taxotere/Cytoxan. I did not research the herceptin part of it.
I have posted positive study results about it someplace and will repost them here as soon as I find them.
IT IS A GREAT CHEMO COMBO MARGO!


__________________


WE WILL PREVAIL





nosurrender

Avatar / Picture

Moderator
Registered:
Posts: 7,476
Reply with quote  #5 

Here is the study about CYTOXAN/TAXOTERE:


Taxotere®/Cytoxan® Superior to Standard Adriamycin®/Cytoxan as Adjuvant Therapy in Breast Cancer

Researchers from the U.S. Oncology Research in Houston reported that the chemotherapy combination Taxotere (docetaxel) plus Cytoxan (cyclophosphamide) provides superior results to the standard Adriamycin (doxorubicin)/ Cytoxan regimen as adjuvant therapy in breast cancer patients. These results were presented at the 28th annual San Antonio Breast Cancer Symposium held December, 8-11, 2005.

Adriamycin/Cytoxan (AC) has long been considered a standard adjuvant chemotherapy combination for the treatment of breast cancer. Thirty years ago, results were published that established AC as the standard adjuvant treatment for breast cancer.

Since then, however, it has been noted that the anthracycline is associated with risks of cardiotoxicity, particularly in patients with underlying cardiac issues or the elderly. Furthermore, Taxotere has demonstrated greater anti-tumor activity than Adriamycin in women with advanced breast cancer. This prompted a trial by researchers affiliated with the U.S. Oncology Research, Inc. in Houston to directly compare AC to Taxotere/Cytoxan (TC) as adjuvant treatment in breast cancer.

This trial included 1016 women with stages I, II or operable stage III breast cancer who had complete surgical excision of their cancer to be randomized to one of the following arms: AC (60/600 mg/m2) or TC (75/600 mg/m2) administered every 3 weeks. Chemotherapy was administered prior to radiation therapy, and tamoxifen was administered following chemotherapy in hormone-positive patients. Patients were randomized between 1997 and 1999. Nearly half of the patients (48%) were node-negative, 41% had 1-3 positive nodes, and 11% had 4 or more positive nodes. At 5 year follow-up, women treated with TC had improved outcomes compared to those treated with AC:

  • Disease-free survival at 5 years was 86% for those treated with TC, compared with 80% for those treated with AC (p=0.015)
  • Overall survival at 5 years was 90% for those treated with TC, compared with 87% for those treated with AC (did not reach statistical significance)
  • In general, TC was better tolerated than AC; patients treated with TC had greater neutropenia while those treated with AC had greater nausea and vomiting
  • Node-positive women had a statistically significant improvement in disease-free survival when treated with TC than AC (HR=.67), however, the improvement in disease-free survival in node-negative women with TC did not reach statistical significance (HR=0.73).
  • Both estrogen receptor positive, and estrogen receptor negative patients achieved similar benefit

The researchers concluded that TC improves disease-free survival compared with AC for the treatment of adjuvant breast cancer. Although cardiac side effects were not presented, the researcher noted that TC does not appear to have the cardiotoxicity issues associated with AC, which is a very important issue for some patients. The presenter stated that TC may now become a legitimate standard treatment option for adjuvant breast cancer.


__________________


WE WILL PREVAIL





MargaretB

Avatar / Picture

Goddess for Life
Registered:
Posts: 1,279
Reply with quote  #6 
Thanks Gina.

Margo
bac10

Avatar / Picture

Goddess Forever
Registered:
Posts: 203
Reply with quote  #7 
I'm on TC.  I'm glad I read this.  It helps to make all I'm going through worth it.  Thanks, Gina.

Bev

__________________
Bev

nosurrender

Avatar / Picture

Moderator
Registered:
Posts: 7,476
Reply with quote  #8 
Bev- remember the Mary Tyler Moore Show???

YOU'RE GONNA MAKE IT
AFTER ALL!!!!!!



__________________


WE WILL PREVAIL





susanmcm

goddess for life
Registered:
Posts: 170
Reply with quote  #9 

Now I know why I did TAC.  I got it all covered. 


__________________
susanmcm
suzolagranola
susan102049
Indigoblue

Avatar / Picture

Queen Blue Sky & Golden Light
Registered:
Posts: 1,681
Reply with quote  #10 
Gina,

You should publish that study; it is a great one!

More women should know about it and your research on Abraxane and Xeloda.  Amazing how much they really don't tell us...

Indi
Previous Topic | Next Topic
Print
Reply

Quick Navigation:

Easily create a Forum Website with Website Toolbox.